Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
-
New drug duo shows promise for hard-to-treat ovarian cancer in japanese women
Disease control OngoingThis study tests two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum chemotherapy. The goal is to see if the combination shrinks tumors and how safe it is. Participants must have measurable disease and …
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New drug combo targets hard-to-treat lung cancer mutation
Disease control OngoingThis study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Promising new cocktail targets tough pancreatic cancer
Disease control OngoingThis study tests a new combination of drugs (avutometinib and defactinib) added to standard chemotherapy for people with advanced pancreatic cancer that has spread. The goal is to see if the new combo is safe and can shrink tumors better than chemo alone. About 40 adults who have…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC